SUN04 Innovative and Advanced Management of Biologics and Small Molecule Inhibitors in Hidradenitis Suppurativa and Beyond
DESCRIPTION
Hidradenitis Suppurativa (HS) is a challenging disease with new therapeutic opportunities on the horizon beyond adalimumab. This session will serve to help the general and medical dermatologist with management and utilization of biologics for HS including complex situations -- when and how to use therapeutic drug monitoring; recommendations and evidence for infectious and lab monitoring for various biologics; management of paradoxical rashes and JAKne; evidence for utilization of dual biologics/small molecules along with safety and monitoring. The final portion of the session will review biologics and small molecules in the pipeline.
LEARNING OBJECTIVES
Outline methods and reasoning behind therapeutic drug monitoring (TDM) in the treatment and management of patients with severe hidradenitis suppurativa with special attention to recent innovations in this arena.
Summarize the management of biologic toxicities in patients with HS with specific discussion of paradoxical reactions, infection risk, screening lab abnormalities (such as hepatitis and TB testing positivity), lupus-like reactions, and candidiasis.
Identify innovations in the HS biologic/small molecule pipeline including potential new avenues for treatment, timing and utilization of combined biologic therapies and beyond.
SCHEDULE
2:30 PM
Therapeutic Drug Monitoring for Biologics in HS
Stella Chen, MD, FAAD
2:40 PM
Lab monitoring and Lab abnormalities -- An Evidence-Based Approach
Julia Mhlaba Riley, MD, FAAD
2:50 PM
Paradoxical Rashes and JAKne Pathophysiology and Management
Alexandra P Charrow, MD, FAAD
3:00 PM
Dual Biologics
Jennifer Lin Hsiao, MD, FAAD
3:10 PM
Biologics and Small Molecule Pipeline
Maria Aleshin, MD, FAAD
3:20 PM
Q and A
SPEAKERS
Maria Aleshin, MD, FAAD
Alexandra P Charrow, MD, FAAD
Brigham and Women's Hospital and Harvard Medical School
Stella Chen, MD, FAAD
Jennifer Lin Hsiao, MD, FAAD
Julia Mhlaba Riley, MD, FAAD
Northwestern Feinberg School of Medicine
SPEAKER DISCLOSURES
Maria Aleshin, MD, FAAD
Mirador – Consultant (1099 relationship)(No Compensation Received); Novartis – Advisory Board(Fees); Santa Ana Bio – Consultant (1099 relationship)(Fees); UCB – Other(Grants/Research Funding);
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Stella Chen, MD, FAAD
No financial relationships exist with ineligible companies.
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Speaker(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Julia Mhlaba Riley, MD, FAAD
AbbVie – Investigator(Fees); MoonLake Immunotherapeutics – Investigator(Fees); Novartis – Investigator(Fees);